{"id":"NCT00405652","sponsor":"Novartis Pharmaceuticals","briefTitle":"Measurement of Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Liver Transplant Recipients","officialTitle":"Measurement of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Liver Transplant Recipients (MyLiver)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-01","primaryCompletion":"2008-09","completion":"2008-09","firstPosted":"2006-11-30","resultsPosted":"2011-03-03","lastUpdate":"2011-03-03"},"enrollment":34,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Liver Transplantation"],"interventions":[{"type":"DRUG","name":"Enteric-coated Mycophenolate sodium (EC-MPS)","otherNames":["myfortic"]}],"arms":[{"label":"Enteric-coated Mycophenolate sodium","type":"EXPERIMENTAL"}],"summary":"Treatment with the immunosuppressive drug mycophenolate mofetil (MMF) may result in gastrointestinal (GI) complications in some patients. This study will assess if a switch from MMF to enteric-coated mycophenolate sodium (EC-MPS) results in improved GI and/or health-related quality of life in liver transplant recipients","primaryOutcome":{"measure":"Changes in Gastrointestinal Symptom Severity and Health Related Quality of Life","timeFrame":"Baseline, End of Study (6-8 weeks)","effectByArm":[{"arm":"Enteric-coated Mycophenolate Sodium","deltaMin":2.88,"sd":0.66}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":12},"locations":{"siteCount":1,"countries":["Germany"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":34},"commonTop":["Abdominal distension","Diarrhoea","Abdominal pain","Nausea","Nasopharyngitis"]}}